GANX Stock Recent News
GANX LATEST HEADLINES
BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.
Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.28 per share a year ago.
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET.
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Presenting Preclinical Data at 2022 International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.